Brief: Cns Pharmaceuticals-On Aug 17, Received Letter From Nasdaq Which Notified Co That It Does Not Presently Comply With Nasdaq's Listing Rule 5550(B)(1)
18/08/2023 22:53
CNS Pharmaceuticals Inc CNSP.O :
* CNS PHARMACEUTICALS-ON AUG 17, RECEIVED LETTER FROM NASDAQ
WHICH
NOTIFIED CO THAT IT DOES NOT PRESENTLY COMPLY WITH NASDAQ'S
LISTING RULE 5550(B)(1)
Source text for Eikon: ID:
Further company coverage: CNSP.O
Recent news on CNS Pharmaceuticals
See all newsCNS Pharmaceuticals Q2 net loss widens, cash rises after financing
CNS Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Brief: Cns Pharmaceuticals Appoints Rami Levin As CEO Effective Jan 1, 2026